Insider Selling: Glaukos (NYSE:GKOS) CEO Sells $10,126,325.00 in Stock

Glaukos Corporation (NYSE:GKOS) CEO Thomas William Burns sold 88,055 shares of Glaukos stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $115.00, for a total value of $10,126,325.00. Following the sale, the chief executive officer directly owned 153,775 shares in the company, valued at $17,684,125. The trade was a 36.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Thomas William Burns also recently made the following trade(s):

• On Friday, January 16th, Thomas William Burns sold 186,945 shares of Glaukos stock. The shares were sold at an average price of $115.00, for a total value of $21,498,675.00.

Glaukos Stock Up 1.5%

Shares of NYSE GKOS opened at $125.98 on Friday. The company has a 50 day simple moving average of $109.93 and a 200 day simple moving average of $96.15. The firm has a market cap of $7.24 billion, a PE ratio of -81.81 and a beta of 0.67. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $163.71. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47.

Glaukos (NYSE:GKOS) last posted its earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The firm had revenue of $133.54 million for the quarter, compared to analyst estimates of $122.55 million. During the same period in the previous year, the firm posted ($0.28) EPS. The company’s revenue for the quarter was up 38.1% compared to the same quarter last year. On average, research analysts forecast that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

GKOS has been the subject of several analyst reports. BTIG Research reaffirmed a “buy” rating and set a $116.00 target price on shares of Glaukos in a research report on Friday, January 2nd. Citigroup increased their price target on Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. Stifel Nicolaus upped their target price on Glaukos from $115.00 to $160.00 and gave the company a “buy” rating in a report on Thursday. Finally, Truist Financial raised their price target on shares of Glaukos from $120.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and a consensus target price of $131.38.

Institutional Investors Weigh In On Glaukos

Large investors have recently added to or reduced their stakes in the business. UMB Bank n.a. increased its holdings in Glaukos by 102.6% in the third quarter. UMB Bank n.a. now owns 312 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 158 shares in the last quarter. Park Place Capital Corp increased its stake in shares of Glaukos by 68.4% in the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock valued at $41,000 after acquiring an additional 162 shares in the last quarter. REAP Financial Group LLC acquired a new position in shares of Glaukos during the 3rd quarter valued at $40,000. AlphaQuest LLC lifted its position in shares of Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock valued at $67,000 after acquiring an additional 633 shares during the period. Finally, Smartleaf Asset Management LLC boosted its stake in Glaukos by 16.2% during the second quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 136 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.